General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More importantly, target-mediated drug disposition (TMDD) introduces a saturable, dose- and concentration-dependent component of clearance that no power-law regression can capture.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“At low concentrations, target-mediated clearance can dominate; at high concentrations, the target is saturated and linear, FcRn-mediated elimination dominates [47,50].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“A practical constraint in biologics first-in-human modelling is that not all of these disposition parameters can be identified simultaneously. FcRn-mediated linear clearance and central volume of distribution generally scale reliably from non-human primate data and can be estimated with reasonable confidence, whereas TMDD parameters such as target baseline concentration, target turnover, and”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“For biologics in particular, this also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Protein Sorting by Transport Vesicles
Rothman, J. E., & Wieland, F. T. (1996) · Science · doi:10.1126/science.272.5259.227 · Cited by 1,153
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Comparison of four basic models of indirect pharmacodynamic responses
Dayneka, N. L., Garg, V., & Jusko, W. J. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061691 · Cited by 821
Self-citationClozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Research works printed but not linked: 3
- D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles (1997).
- W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, Applied Therapeutics, Inc., Vancouver, 1992, Ch. 2.
- J. G. Wagner. A new generalized nonlinear pharmacokinetic model and its implications. In J. G. Wagner (ed.), Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971, pp. 302–317.
Cited by
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Shah, D. K., & Betts, A. M. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9232-2 · Cited by 422
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Diversity of Mechanism-Based Pharmacodynamic Models
Mager, D. E., Wyska, E., & Jusko, W. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.510 · Cited by 345
Self-citationAdvani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M., Bornstein, G. G., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 305
Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., Veal, G., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 296
Approximations of the Target-Mediated Drug Disposition Model and Identifiability of Model Parameters
Gibiansky, L., Gibiansky, E., Kakkar, T., & Ma, P. (2008) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-008-9102-8 · Cited by 272
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Bajaj, G., Wang, X., Agrawal, S., Gupta, M., Roy, A., & Feng, Y. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12143 · Cited by 264
Target-mediated drug disposition and dynamics
Mager, D. E. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.041 · Cited by 244
Self-citationCremers, S. C. L. M., Pillai, G. (., & Papapoulos, S. E. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544060-00001 · Cited by 238
del Amo, E. M., & Urtti, A. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.05.003 · Cited by 231
Dostalek, M., Gardner, I., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 230
Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Mager, D. E., & Krzyzanski, W. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-6650-0 · Cited by 225
Self-citationTibbitts, J., Canter, D., Graff, R., Smith, A., & Khawli, L. A. (2016) · mAbs · doi:10.1080/19420862.2015.1115937 · Cited by 209
Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems
Glassman, P. M., & Muzykantov, V. R. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257113 · Cited by 209
A Guide to Rational Dosing of Monoclonal Antibodies
Bai, S., Jorga, K., Xin, Y., Jin, D., Zheng, Y., Damico-Beyer, L. A., Gupta, M., Tang, M., Allison, D. E., Lu, D., et al. (2012) · Clinical Pharmacokinetics · doi:10.2165/11596370-000000000-00000 · Cited by 165
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
Dua, P., Hawkins, E., & van der Graaf, P. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.41 · Cited by 162
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease
Shi, F., Xue, R., Zhou, X., Shen, P., Wang, S., & Yang, Y. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1973493 · Cited by 157
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Shor, B., Gerber, H., & Sapra, P. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.014 · Cited by 149
Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges
Zou, H., Banerjee, P., Leung, S. S. Y., & Yan, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00997 · Cited by 161
Vey, N., Karlin, L., Sadot-Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24832 · Cited by 142
Agoram, B. M., Martin, S. W., & van der Graaf, P. H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.002 · Cited by 146
Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans
Mager, D. E., Woo, S., & Jusko, W. J. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.16 · Cited by 141
Self-citationMechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 170
A biomimetic approach for enhancing the in vivo half-life of peptides
Penchala, S., Miller, M. R., Pal, A., Dong, J., Madadi, N. R., Xie, J., Joo, H., Tsai, J. W., Batoon, P. H. M., Samoshin, V. V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1907 · Cited by 152
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.371 · Cited by 138
“These programmes are underpinned by pharmacokinetic studies: the clinical benefit of rituximab IV and trastuzumab IV is assumed to be dependent on serum concentrations of the respective antibodies (Mager and Jusko, 2001; Yin et al, 2010).”
BackgroundUpdates on The Use of Liposomes for Active Tumor Targeting in Cancer Therapy
Yan, W., Leung, S. S., & To, K. K. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0308 · Cited by 134
Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient
Peck, R. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052446 · Cited by 140
Wynne, C., Harvey, V., Schwabe, C., Waaka, D., McIntyre, C., & Bittner, B. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012436560 · Cited by 128
The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance
Jamei, M., Marciniak, S., Edwards, D., Wragg, K., Feng, K., Barnett, A., & Rostami-Hodjegan, A. (2013) · In Silico Pharmacology · doi:10.1186/2193-9616-1-9 · Cited by 124
Burmester, G. R., Feist, E., Sleeman, M., Wang, B., White, B., & Magrini, F. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146225 · Cited by 127
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Cilliers, C., Guo, H., Liao, J., Christodolu, N., & Thurber, G. M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9940-z · Cited by 125
In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant
de Witte, W. E. A., Danhof, M., van der Graaf, P. H., & de Lange, E. C. M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.008 · Cited by 121
An, G. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1545 · Cited by 123
Sutjandra, L., Rodriguez, R. D., Doshi, S., Ma, M., Peterson, M. C., Jang, G. R., Chow, A. T., & Ruixo, J. J. P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594240-000000000-00000 · Cited by 123
Dupilumab: Mechanism of action, clinical, and translational science
McCann, M. R., Kosloski, M. P., Xu, C. R., Davis, J. D., & Kamal, M. A. (2024) · Clinical and Translational Science · doi:10.1111/cts.13899 · Cited by 128
Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification
Peletier, L. A., & Gabrielsson, J. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9260-6 · Cited by 119
Betts, A. M., Keunecke, A., van Steeg, T. J., van der Graaf, P. H., Avery, L. B., Jones, H. M., & Berkhout, J. (2018) · mAbs · doi:10.1080/19420862.2018.1462429 · Cited by 120
Precision Medicine: A New Paradigm in Therapeutics
Akhoon, N. (2021) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_375_19 · Cited by 132
Phase 0/microdosing approaches: time for mainstream application in drug development?
Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 119
Gibiansky, L., & Gibiansky, E. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902992901 · Cited by 111
Gill, K. L., Gardner, I. B., Li, L., & Jamei, M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9819-4 · Cited by 111
Ng, C. M., Stefanich, E. G., Anand, B. S., Fielder, P. J., & Vaickus, L. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8814-3 · Cited by 109
Ternant, D., Bejan‐Angoulvant, T., Passot, C., Mulleman, D., & Paintaud, G. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0296-9 · Cited by 111
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Thomas, V. A., & Balthasar, J. P. (2019) · Antibodies · doi:10.3390/antib8040056 · Cited by 109
Drug Development of Therapeutic Monoclonal Antibodies
Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 110
Model‐based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
Feng, Y., Masson, E., Dai, D., Parker, S. M., Berman, D., & Roy, A. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12323 · Cited by 103
Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody
Urva, S., Yang, V. C.-M., & Balthasar, J. P. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21918 · Cited by 108
Betts, A. M., Clark, T. H., Yang, J., Treadway, J. L., Li, M., Giovanelli, M. A., Abdiche, Y. N., Stone, D. M., & Paralkar, V. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164129 · Cited by 107
Vu, T. C., Ma, P., Chen, J. S., Hoon, J. N. J. M. D., Hecken, A. V., Yan, L. L., Wu, L. S., Hamilton, L. J., & Vargas, G. A. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2183-6 · Cited by 104
Goldberg, A. Z., Geppert, T. D., Schiopu, E., Frech, T., Hsu, V. M., Simms, R. W., Peng, S. L., Yao, Y., Elgeioushi, N., Chang, L. L., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4492 · Cited by 106
Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours
Gibiansky, L. V., Sutjandra, L., Doshi, S., Zheng, J., Sohn, W. Y., Peterson, M. C., Jang, G. R., Chow, A. T., & Ruixo, J. J. P. (2012) · Clinical Pharmacokinetics · doi:10.2165/11598090-000000000-00000 · Cited by 101
Espié, P., He, Y., Koo, P., Sickert, D., Dupuy, C., Chokoté, E., Schuler, R., Mergentaler, H., Ristov, J., Milojevic, J., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15661 · Cited by 98
Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Ball, K., Dovedi, S. J., Vajjah, P., & Phipps, A. (2023) · mAbs · doi:10.1080/19420862.2023.2181016 · Cited by 99
Protein therapeutics: new applications for pharmacogenetics
Krejsa, C. M., Rogge, M. C., & Sadée, W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2039 · Cited by 106
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Geraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck-Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J.-E. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 96
Cao, Y., & Jusko, W. J. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9372-2 · Cited by 95
Self-citationPharmacokinetic Modeling of the Subcutaneous Absorption of Therapeutic Proteins
Kagan, L. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059121 · Cited by 99
Daix, T., Mathonnet, A., Brakenridge, S. C., Dequin, P., Mira, J. P., Berbille, F., Morre, M., Jeannet, R., Blood, T. M., Unsinger, J., et al. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01109-w · Cited by 102
Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models
Yan, X., Mager, D. E., & Krzyzanski, W. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9142-8 · Cited by 91
Self-citationNg, C. M., Joshi, A., Dedrick, R. L., Garovoy, M. R., & Bauer, R. J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-5642-4 · Cited by 92
Moving from Basic Toward Systems Pharmacodynamic Models
Jusko, W. J. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23590 · Cited by 86
Self-citationGlassman, P. M., & Balthasar, J. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9482-0 · Cited by 93
Bender, B. C., Leipold, D. D., Xu, K., Shen, B., Tibbitts, J., & Friberg, L. E. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9618-3 · Cited by 88
Geary, R. S., Wancewicz, E. V., Matson, J. E., Pearce, M. E., Siwkowski, A. M., Swayze, E. E., & Bennett, F. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.013 · Cited by 87
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis
Ternant, D., Ducourau, É., Perdriger, A., Corondan, A., Goff, B. L., Devauchelle‐Pensec, V., Solau‐Gervais, E., Watier, H., Goupille, P., Paintaud, G., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12313 · Cited by 88
Agoram, B. M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03297.x · Cited by 85
Wang, Y., Krzyżański, W., Doshi, S., Xiao, J. J., Ruixo, J. J. P., & Chow, A. T. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9234-9 · Cited by 83
Pharmacokinetics of Peptide–Fc Fusion Proteins
Benjamin, W. U., & Sun, Y. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23783 · Cited by 84
Lowe, P. J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R., & Howard, D. (2007) · Xenobiotica · doi:10.1080/00498250701648008 · Cited by 81
Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys
Xiao, J. J., Krzyżański, W., Wang, Y., Li, H., Rose, M. J., Ma, M., Wu, Y., Hinkle, B., & Ruixo, J. J. P. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9222-0 · Cited by 85
Luu, K. T., Bergqvist, S., Chen, E., Hu‐Lowe, D. D., & Kraynov, E. A. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191999 · Cited by 84
Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Interferon-β1a in Monkeys
Mager, D. E., Neuteboom, B., Efthymiopoulos, C., Munafo, A., & Jusko, W. J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049502 · Cited by 80
Self-citationCapacity limits of asialoglycoprotein receptor-mediated liver targeting
Bon, C., Höfer, T., Bousquet‐mélou, A., Davies, M. R., & Krippendorff, B. (2017) · mAbs · doi:10.1080/19420862.2017.1373924 · Cited by 78
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
Li, Z., Radin, A. R., Li, M., Hamilton, J. D., Kajiwara, M., Davis, J. D., Takahashi, Y., Hasegawa, S., Ming, J. E., DiCioccio, A. T., et al. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.798 · Cited by 80
Ikeda, M., Ohkawa, S., Okusaka, T., Mitsunaga, S., Kobayashi, S., Morizane, C., Suzuki, I., Yamamoto, S., & Furuse, J. (2014) · Cancer Science · doi:10.1111/cas.12368 · Cited by 73
Ribba, B., Boetsch, C., Nayak, T. K., Grimm, H. P., Charo, J., Evers, S., Klein, C., Tessier, J. J. L., Charoin, J. E., Phipps, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2953 · Cited by 77
Marathe, A., Peterson, M. C., & Mager, D. E. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137703 · Cited by 77
Self-citationPeptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry
Κάτσιλα, Θ., Siskos, A., & Tamvakopoulos, C. (2011) · Mass Spectrometry Reviews · doi:10.1002/mas.20340 · Cited by 73
Singh, A. P., Shin, Y. G., & Shah, D. K. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1626-1 · Cited by 72
Pharmacological characterization of PF‐00547659, an anti‐human MAdCAM monoclonal antibody
Pullen, N., Molloy, E. J., Carter, D., Syntin, P., Clemo, F. A. S., Finco‐Kent, D., Reagan, W. J., Zhao, S., Kawabata, T. T., & Sreckovic, S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00137.x · Cited by 71
Influence of Molecular size on the clearance of antibody fragments
Li, Z., Krippendorff, B., & Shah, D. K. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2219-y · Cited by 72
Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies
Malik, P. R. V., & Edginton, A. N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1482278 · Cited by 75
Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69
Eke, A. C., Gebreyohannes, R. D., Fernandes, M. F. S., & Pillai, V. C. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2227 · Cited by 84
Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies
Liu, S., Verma, A., Kettenberger, H., Richter, W. F., & Shah, D. K. (2021) · mAbs · doi:10.1080/19420862.2021.1993769 · Cited by 72
Targeting therapeutics to endothelium: are we there yet?
Kiseleva, R. Y., Glassman, P. M., Greineder, C. F., Hood, E. D., Shuvaev, V. V., & Muzykantov, V. R. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0464-6 · Cited by 67
Li, H., Ortiz, R., Tran, L. T., Salimi-Moosavi, H., Malella, J., James, C. A., & Lee, J. W. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9435-5 · Cited by 65
Ternant, D., Berkane, Z., Picon, L., Gouilleux‐Gruart, V., Colombel, J., Allez, M., Louis, E. J., & Paintaud, G. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0225-3 · Cited by 65
Schropp, J., Khot, A., Shah, D. K., & Koch, G. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12369 · Cited by 67
Li, L., Gardner, I. B., Dostálek, M., & Jamei, M. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9640-5 · Cited by 67
Woo, S., Krzyżański, W., & Jusko, W. J. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9074-0 · Cited by 64
Self-citationCampagne, O., Delmas, A., Fouliard, S., Chenel, M., Chichili, G. R., Li, H., Alderson, R. F., Scherrmann, J., & Mager, D. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2265 · Cited by 65
Self-citationKeyvani, F., GhavamiNejad, P., Saleh, M. A., Soltani, M., Zhao, Y., Sadeghzadeh, S., Shakeri, A., Chelle, P., Zheng, H., Rahman, F. A., et al. (2024) · Advanced Science · doi:10.1002/advs.202309027 · Cited by 69
Receptor-Mediated Pharmacokinetic/Pharmacodynamic Model of Interferon-β 1a in Humans
Mager, D. E., & Jusko, W. J. (2002) · Pharmaceutical Research · doi:10.1023/a:1020468902694 · Cited by 63
Self-citationLevy, G., Mager, D. E., Cheung, W. K., & Jusko, W. J. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10345 · Cited by 62
Self-citation
Metadata
- Authors
- Mager, D. E., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2001-12
- Volume
- 28
- Issue
- 6
- Pages
- 507-532
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W28215347
- Cited by
- 605
- References
- 40
- Citations by year
- 2026: 40 · 2025: 27 · 2024: 30 · 2023: 32 · 2022: 31 · 2021: 31 · 2020: 40 · 2019: 37 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 41 · 2014: 31 · 2013: 36 · 2012: 32
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 57980, R01GM057980)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- target-mediated drug disposition, nonlinear pharmacokinetics, receptor-mediated endocytosis, pharmacokinetic modeling, dose-dependent clearance, drug elimination, bosentan, interferon beta-1a, enzyme inhibitors, receptor antagonists
- MeSH terms
- Bosentan, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Fluorenes, Humans, Hydantoins, Male, Models, Chemical, Pharmacokinetics, Sulfonamides, Drug Delivery Systems, Interferon-beta, Nonlinear Dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.